Loading…
Trial sponsor collaborator change
| collaborators | AstraZeneca,Celgene Corporation,Merck Sharp & Dohme LLC,Novartis Pharmaceuticals,Pfizer,Boehringer Ingelheim,Bristol-Myers Squibb,iOMEDICO AG,Eli Lilly and Company,Roche Pharma AG,Takeda,Amgen,Janssen-Cilag G.m.b.H,GlaxoSmithKline,Daiichi Sankyo,Regeneron Pharmaceuticals,Gilead Sciences | → | AstraZeneca,Celgene Corporation,Merck Sharp & Dohme LLC,Novartis Pharmaceuticals,Pfizer,Boehringer Ingelheim,Bristol-Myers Squibb,iOMEDICO AG,Eli Lilly and Company,Roche Pharma AG,Takeda,Amgen,Janssen-Cilag G.m.b.H,GlaxoSmithKline,Regeneron Pharmaceuticals,Astellas Pharma Global Development, Inc.,Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company,Daiichi Sankyo Deutschland GmbH,Gilead Sciences |
Seven dimensions, unsigned magnitude 0–100. Direction is resolved separately, per entity, because one event is good for one name and bad for another.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.